IDX
Integral Diagnostics Ltd
- Announcements, last 12 months
- 69
- Price sensitive, last 12 months
- 11
- Followed on InvestorPA
- Some (Among the 20% most-followed companies on InvestorPA)
Latest announcements
Sign in to see all IDX announcements.
Guidance history
| 25 Aug 2026 | Revenue of $788.7m, Operating EBITDA of $164.8m, Operating NPAT of $47.4m, Operating diluted EPS of 12.6 cents | |
| 10 Aug 2026 | Revenue: $788m-$790m, EBITDA: $164m-$165m, FY26 | |
| 24 Feb 2026 | Continued revenue growth is expected, with the FY26 Operating EBITDA margin forecast to be ~21.0%, driven by the ramp-up of new greenfield sites and brownfield investments, scale benefits including increased use of teleradiology and further procurement efficiencies, and supported by further de-regulation of MRIs and the National Lung Cancer Screening Program. Group FY26 replacement and growth capex is expected to be between $45.0m to $55.0m, and the Group Net Debt/EBITDA (pre-AASB16) is projected to continue to trend down in line with the Group's target ratio of 2.5x or less over time. |
Sign in to see the full guidance history.
Most followed in Health Care
Follow IDX to get its announcements emailed to you, with AI summaries, the full announcement and guidance history, and its most significant announcements.
Sign in